We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Professor Emeritus David L. Sackett, Developer of Evidence Based Medicine

By LabMedica International staff writers
Posted on 01 Jun 2015
Professor Emeritus David Lawrence Sackett, MD, widely regarded as the father of evidence based medicine (EBM), died on May 13, 2015, in Canada.

Prof. More...
Sackett obtained his medical degree at the University of Illinois (Champaign, USA) and was drafted into the US Public Health Service in 1962 as a result of the Cuban missile crisis. He received a master’s degree in epidemiology from Harvard University (Boston, MA, USA), and became interested in how the methods of epidemiology could be applied to clinical medicine, calling the combination clinical epidemiology. In 1968, the 32 year old Sackett founded Canada’s first department of clinical epidemiology and biostatistics at McMaster University (Hamilton, ON, Canada), coining the term EBM.

He remained at McMaster University until 1994, when he left to found the international Center for Evidence-Based Medicine at the University of Oxford (United Kingdom). He officially retired from academia and clinical practice in 1999, and returned to Canada to establish the Trout Research & Education Centre at McMaster. During his career, he was instrumental in developing EBM, a medical approach based on scientific evidence and critical appraisal rather than conventional wisdom.

He developed and mentored a new breed of applied clinician-scientists, and worked with them to create and disseminate EBM throughout the world. His collaborative research teams were the first to validate the efficacy of aspirin and carotid endarterectomy for patients with threatened stroke, to develop effective strategies for helping hypertensive patients, and to generate compelling evidence of the effectiveness of nurse practitioners. He published 10 books, about 50 book chapters, and over 400 papers in medical and scientific journals.

“David Sackett was a true transformer of health care. He questioned established beliefs, and explored emerging areas,” said Holger Schünemann, chair of the department of epidemiology and biostatistics at the McMaster School of Medicine. “His legacy is carried forward through his influential role on clinical trials, systematic reviews, evidence-based medicine and health education worldwide.”

Related Links:

University of Illinois
McMaster University
University of Oxford



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.